Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Current Assets (2016 - 2025)

Historic Current Assets for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to $237076.0.

  • Regen BioPharma's Current Assets rose 3649.93% to $237076.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $237076.0, marking a year-over-year increase of 3649.93%. This contributed to the annual value of $274628.0 for FY2025, which is 9157.73% up from last year.
  • Per Regen BioPharma's latest filing, its Current Assets stood at $237076.0 for Q4 2025, which was up 3649.93% from $274628.0 recorded in Q3 2025.
  • Regen BioPharma's Current Assets' 5-year high stood at $994124.0 during Q3 2021, with a 5-year trough of $62616.0 in Q2 2023.
  • Moreover, its 5-year median value for Current Assets was $181581.5 (2023), whereas its average is $281922.1.
  • As far as peak fluctuations go, Regen BioPharma's Current Assets soared by 86311.18% in 2021, and later plummeted by 8577.83% in 2023.
  • Over the past 5 years, Regen BioPharma's Current Assets (Quarter) stood at $641157.0 in 2021, then crashed by 70.13% to $191528.0 in 2022, then dropped by 25.97% to $141795.0 in 2023, then rose by 22.49% to $173683.0 in 2024, then surged by 36.5% to $237076.0 in 2025.
  • Its last three reported values are $237076.0 in Q4 2025, $274628.0 for Q3 2025, and $179108.0 during Q2 2025.